Compare Stocks: PYPD, ENTA, EYPT, and PALI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTA Enanta Pharmaceuticals	$12.70 -4.1%	$13.49	$7.05 ▼ $17.15	$385.62M	0.93	224,571 shs	312,790 shs
EYPT Eyepoint Pharmaceuticals	$4.25 -2.1%	$10.03	$3.95 ▼ $19.11	$374.16M	1.63	6.99 million shs	4.32 million shs
PALI Palisade Bio	$2.01 -2.0%	$2.03	$0.53 ▼ $2.86	$357.26M	1.53	1.64 million shs	2.65 million shs
PYPD PolyPid	$5.16 -0.8%	$4.88	$3.06 ▼ $5.73	$99.23M	1.41	112,368 shs	69,605 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTA Enanta Pharmaceuticals	-4.08%	-9.42%	-6.07%	+6.72%	+52.46%
EYPT Eyepoint Pharmaceuticals	-2.07%	-7.00%	-67.43%	-67.38%	-68.63%
PALI Palisade Bio	-1.95%	-1.71%	-6.07%	+17.54%	+272.91%
PYPD PolyPid	-0.77%	-2.09%	+9.09%	+11.69%	+49.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTA Enanta Pharmaceuticals	$12.70 -4.1%	$13.49	$7.05 ▼ $17.15	$385.62M	0.93	224,571 shs	312,790 shs
EYPT Eyepoint Pharmaceuticals	$4.25 -2.1%	$10.03	$3.95 ▼ $19.11	$374.16M	1.63	6.99 million shs	4.32 million shs
PALI Palisade Bio	$2.01 -2.0%	$2.03	$0.53 ▼ $2.86	$357.26M	1.53	1.64 million shs	2.65 million shs
PYPD PolyPid	$5.16 -0.8%	$4.88	$3.06 ▼ $5.73	$99.23M	1.41	112,368 shs	69,605 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTA Enanta Pharmaceuticals	-4.08%	-9.42%	-6.07%	+6.72%	+52.46%
EYPT Eyepoint Pharmaceuticals	-2.07%	-7.00%	-67.43%	-67.38%	-68.63%
PALI Palisade Bio	-1.95%	-1.71%	-6.07%	+17.54%	+272.91%
PYPD PolyPid	-0.77%	-2.09%	+9.09%	+11.69%	+49.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTA Enanta Pharmaceuticals	2.71	Moderate Buy	$19.50	53.54% Upside
EYPT Eyepoint Pharmaceuticals	2.27	Hold	$25.70	504.71% Upside
PALI Palisade Bio	3.00	Buy	$9.00	347.76% Upside
PYPD PolyPid	2.50	Moderate Buy	$11.33	119.64% Upside

Current Analyst Ratings Breakdown

Latest PYPD, ENTA, EYPT, and PALI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	EYPT Eyepoint Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$20.00 ➝ $4.00
9/1/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	EYPT Eyepoint Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$5.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
8/17/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
8/17/2026	EYPT Eyepoint Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00
8/17/2026	EYPT Eyepoint Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/23/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTA Enanta Pharmaceuticals	$65.32M	5.66	N/A	N/A	$3.03 per share	4.19
EYPT Eyepoint Pharmaceuticals	$31.37M	11.68	N/A	N/A	$3.70 per share	1.15
PALI Palisade Bio	$250K	1,401.13	N/A	N/A	$0.87 per share	2.31
PYPD PolyPid	N/A	N/A	N/A	N/A	$0.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTA Enanta Pharmaceuticals	-$81.89M	-$2.41	N/A	N/A	N/A	-96.89%	-61.84%	-20.70%	11/16/2026 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
PALI Palisade Bio	-$16.78M	-$0.48	N/A	N/A	N/A	N/A	-33.47%	-31.79%	11/9/2026 (Estimated)
PYPD PolyPid	-$34.17M	-$1.48	N/A	N/A	N/A	N/A	-311.08%	-150.83%	11/11/2026 (Estimated)

Latest PYPD, ENTA, EYPT, and PALI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PYPD PolyPid	-$0.3775	-$0.35	+$0.0275	-$0.35	$0.30 million	N/A
8/10/2026	Q3 2026	ENTA Enanta Pharmaceuticals	-$0.5095	-$0.67	-$0.1605	-$0.67	$16.76 million	$14.36 million
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTA Enanta Pharmaceuticals	N/A	3.76	3.76
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
PALI Palisade Bio	N/A	24.26	24.26
PYPD PolyPid	N/A	1.35	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTA Enanta Pharmaceuticals	94.99%
EYPT Eyepoint Pharmaceuticals	99.41%
PALI Palisade Bio	11.79%
PYPD PolyPid	26.47%

Insider Ownership

Company	Insider Ownership
ENTA Enanta Pharmaceuticals	11.48%
EYPT Eyepoint Pharmaceuticals	5.13%
PALI Palisade Bio	0.07%
PYPD PolyPid	24.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTA Enanta Pharmaceuticals	160	29.12 million	25.78 million	Optionable
EYPT Eyepoint Pharmaceuticals	120	86.21 million	81.79 million	Optionable
PALI Palisade Bio	10	174.27 million	174.15 million	Not Optionable
PYPD PolyPid	80	19.08 million	14.37 million	No Data

PYPD, ENTA, EYPT, and PALI Headlines

Recent News About These Companies

PolyPid Ltd. (NASDAQ:PYPD) Sees Large Drop in Short Interest

August 30, 2026 | marketbeat.com

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

AIGH Capital Management LLC Purchases Shares of 1,504,741 PolyPid Ltd. $PYPD

August 17, 2026 | marketbeat.com

What is HC Wainwright's Forecast for PolyPid Q3 Earnings?

August 14, 2026 | marketbeat.com

HC Wainwright Issues Negative Estimate for PolyPid Earnings

August 13, 2026 | marketbeat.com

PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...

August 12, 2026 | finance.yahoo.com

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

August 12, 2026 | marketbeat.com

PolyPid Q2 Earnings Call Highlights

August 12, 2026 | marketbeat.com

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 12, 2026 | globenewswire.com

PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD)

July 31, 2026 | markets.businessinsider.com

PolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026

July 30, 2026 | quiverquant.comQ

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

July 30, 2026 | globenewswire.com

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

July 29, 2026 | globenewswire.com

PolyPid Ltd.: PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada

July 21, 2026 | finanznachrichten.de

PolyPid Locks in a Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential

July 21, 2026 | markets.businessinsider.com

PolyPid, Azurity sign surgical site infection drug deal

July 21, 2026 | reuters.com

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

July 21, 2026 | globenewswire.com

Lilly’s $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid’s Asset is Hiding in Plain Sight

June 27, 2026 | theglobeandmail.com

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

June 1, 2026 | globenewswire.com

PolyPid Stock Short Interest Report | NASDAQ:PYPD | Benzinga

May 22, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PYPD, ENTA, EYPT, and PALI Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

$12.70 -0.54 (-4.08%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$12.70 0.00 (-0.04%)

As of 09/10/2026 07:30 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$4.25 -0.09 (-2.07%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$4.25 +0.00 (+0.05%)

As of 09/10/2026 07:56 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Palisade Bio NASDAQ:PALI

$2.01 -0.04 (-1.95%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$2.04 +0.04 (+1.74%)

As of 09/10/2026 07:30 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

PolyPid NASDAQ:PYPD

$5.16 -0.04 (-0.77%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$5.16 +0.00 (+0.10%)

As of 09/10/2026 07:30 PM Eastern

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYPD, ENTA, EYPT, and PALI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYPD, ENTA, EYPT, and PALI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYPD, ENTA, EYPT, and PALI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PYPD, ENTA, EYPT, and PALI Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

Eyepoint Pharmaceuticals NASDAQ:EYPT

Palisade Bio NASDAQ:PALI

PolyPid NASDAQ:PYPD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYPD, ENTA, EYPT, and PALI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYPD, ENTA, EYPT, and PALI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYPD, ENTA, EYPT, and PALI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PYPD, ENTA, EYPT, and PALI Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

Eyepoint Pharmaceuticals NASDAQ:EYPT

Palisade Bio NASDAQ:PALI

PolyPid NASDAQ:PYPD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools